

# Mitchell Sabloff

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2453158/publications.pdf>

Version: 2024-02-01

113  
papers

3,199  
citations

172207

29  
h-index

161609

54  
g-index

114  
all docs

114  
docs citations

114  
times ranked

4346  
citing authors

#	ARTICLE	IF	CITATIONS
1	Autologous Hematopoietic Stem Cell Transplantation for Liver Transplant Recipients With Recurrent Primary Sclerosing Cholangitis: A Pilot Study. <i>Transplantation</i> , 2022, 106, 562-574.	0.5	7
2	The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes. <i>Annals of Hematology</i> , 2022, 101, 1023-1030.	0.8	3
3	Total Body Irradiation for Hematopoietic Stem Cell Transplantation: What Can We Agree on?. <i>Current Oncology</i> , 2021, 28, 903-917.	0.9	29
4	Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2295-2297.	0.6	7
5	Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN study. <i>British Journal of Haematology</i> , 2021, 194, 319-324.	1.2	6
6	Breaking the Age Barrier: Physicians' Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 617.e1-617.e7.	0.6	14
7	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 921.e1-921.e10.	0.6	11
8	The Impact of Oral Hypoglycemics and Statins on Outcomes in Myelodysplastic Syndromes. <i>Blood</i> , 2021, 138, 3064-3064.	0.6	1
9	An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring. <i>Leukemia</i> , 2020, 34, 1394-1406.	3.3	23
10	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146.	2.0	14
11	Plerixafor in combination with chemotherapy and/or hematopoietic cell transplantation to treat acute leukemia: A systematic review and meta-analysis of preclinical and clinical studies. <i>Leukemia Research</i> , 2020, 97, 106442.	0.4	15
12	Revised 15-item MDS-specific frailty scale maintains prognostic potential. <i>Leukemia</i> , 2020, 34, 3434-3438.	3.3	8
13	Selecting the optimal targeted therapy for relapsed B-acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2271-2273.	0.6	0
14	Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S161.	2.0	0
15	Total body irradiation (18% Gy) without chemotherapy as conditioning for allogeneic hematopoietic cell transplantation in refractory acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 1454-1456.	1.3	2
16	Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2020, 136, 37-38.	0.6	16
17	High Doses of Targeted Radiation with Anti-CD45 Iodine (131I) Apamistamab [lomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 30-31.	0.6	2
18	Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [lomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered. <i>Blood</i> , 2020, 136, 42-44.	0.6	3

#	ARTICLE	IF	CITATIONS
19	Inferior Outcomes with a High LSC17 Score Can be Improved with Flag-IDA. <i>Blood</i> , 2020, 136, 35-36.	0.6	0
20	Fatigue, However Measured, Continues to Refine Prognosis in Higher Risk MDS: An MDS-CAN Study. <i>Blood</i> , 2020, 136, 41-43.	0.6	1
21	High Transfusion Dependence and Serum Ferritin but Not Transferrin Saturation Predict Inferior Clinical Outcomes in Patients with MDS. <i>Blood</i> , 2020, 136, 47-48.	0.6	0
22	Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2398-2407.	2.0	21
23	Evaluating dose-limiting toxicities of MDM2 inhibitors in patients with solid organ and hematologic malignancies: A systematic review of the literature. <i>Leukemia Research</i> , 2019, 86, 106222.	0.4	12
24	Re-Induction and Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial. <i>Blood</i> , 2019, 134, 5642-5642.	0.6	3
25	Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine. <i>Blood</i> , 2019, 134, 846-846.	0.6	55
26	Prognostic Performance of Frailty Measures in MDS Patients Treated with Hypomethylating Agents. <i>Blood</i> , 2019, 134, 4245-4245.	0.6	3
27	Trial in Progress: Feasibility and Validation Study of the LSC17 Score in Acute Myeloid Leukemia Patients. <i>Blood</i> , 2019, 134, 2682-2682.	0.6	6
28	Acute Myeloid Leukemia (AML) Treated with Azacitidine: Survival Outcomes for Patients Who Complete More Than Six Cycles Are Similar to High-Risk Myelodysplastic Syndrome/Low Blast Count AML. <i>Blood</i> , 2019, 134, 5156-5156.	0.6	0
29	Persistent Red Blood Cell (RBC) Transfusion Is Associated with Increased Mortality Risk in Transfusion-Dependent (TD) Patients with Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS+). <i>Blood</i> , 2019, 134, 3012-3012.	0.6	0
30	Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less. <i>Blood</i> , 2019, 134, 3263-3263.	0.6	0
31	Intermittent Transfusion Independence Is Associated with Improved Overall Survival in Patients with Transfusion Dependent MDS. <i>Blood</i> , 2019, 134, 5416-5416.	0.6	1
32	Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers. <i>Blood Cancer Journal</i> , 2018, 8, 14.	2.8	3
33	Rapid Decrease in KRT14 and TP53 mRNA Expression in the Buccal Mucosa of Patients Receiving Total-Body Irradiation for Allogeneic Stem Cell Transplantation. <i>Radiation Research</i> , 2018, 189, 213-218.	0.7	2
34	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71
35	A Dose Escalation Study of Total Marrow Irradiation and Autologous Stem-Cell Transplantation for Relapsed Multiple Myeloma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S127.	2.0	2
36	Effect of Donor Age and Donor Relatedness on Time to Allogeneic Hematopoietic Cell Transplantation in Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2466-2470.	2.0	7

#	ARTICLE	IF	CITATIONS
37	Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy. <i>Cancer Discovery</i> , 2018, 8, 1376-1389.	7.7	40
38	Health Related Quality of Life Remains Stable over Time in Myelodysplastic Syndrome: An MDS-CAN Prospective Study. <i>Blood</i> , 2018, 132, 4850-4850.	0.6	2
39	Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy. <i>Blood</i> , 2018, 132, 5232-5232.	0.6	0
40	Reduced Intensity Conditioned Sibling Transplantation Versus No Transplant in Intermediate or High Risk Acute Myeloid Leukemia: A Prospective Multi-Center Study in Patients 50-70 Years in First Complete Remission and with at Least One Potential Sibling Donor (ClinTrialGov 00342316). <i>Blood</i> , 2018, 132, 205-205.	0.6	2
41	Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 767-775.	2.0	41
42	Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate. <i>Pharmacotherapy</i> , 2017, 37, 684-691.	1.2	20
43	High Dose Total Body Irradiation for Refractory Acute Myeloid Leukemia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, S179.	0.4	0
44	Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche. <i>Nature Cell Biology</i> , 2017, 19, 1336-1347.	4.6	150
45	A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry. <i>Annals of Hematology</i> , 2017, 96, 2025-2029.	0.8	12
46	Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2096-2101.	2.0	27
47	Micro-RNA Profiling of Exosomes from Marrow-Derived Mesenchymal Stromal Cells in Patients with Acute Myeloid Leukemia: Implications in Leukemogenesis. <i>Stem Cell Reviews and Reports</i> , 2017, 13, 817-825.	5.6	65
48	ITACA: A new validated international erythropoietic stimulating agent response score that further refines the predictive power of previous scoring systems. <i>American Journal of Hematology</i> , 2017, 92, 1037-1046.	2.0	20
49	MDS-Can-It: A New Validated International ESA-Response Score that Further Refines the Predictive Power of the Nordic Scoring System. <i>Leukemia Research</i> , 2017, 55, S131-S132.	0.4	0
50	Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis. <i>British Journal of Haematology</i> , 2017, 179, 83-97.	1.2	48
51	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. <i>Blood</i> , 2017, 130, 1156-1164.	0.6	210
52	Total Body Irradiation without Chemotherapy as Conditioning for an Allogeneic Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia. <i>Case Reports in Hematology</i> , 2016, 2016, 1-7.	0.3	2
53	Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study. <i>British Journal of Haematology</i> , 2016, 174, 88-101.	1.2	78
54	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. <i>Cancer</i> , 2016, 122, 3005-3014.	2.0	45

#	ARTICLE	IF	CITATIONS
55	Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation. <i>JAMA Neurology</i> , 2016, 73, 652.	4.5	71
56	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2016, 34, 1864-1871.	0.8	61
57	Total Body Irradiation in Relapsed Follicular Lymphoma: Outcomes and Early Toxicity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E498-E499.	0.4	1
58	PO-0667: Second malignancies after TBI in AHCT for relapsed follicular lymphoma. <i>Radiotherapy and Oncology</i> , 2016, 119, S311.	0.3	1
59	83: Late Toxicity after TBI in AHCT for Relapsed Follicular Lymphoma. <i>Radiotherapy and Oncology</i> , 2016, 120, S32-S33.	0.3	1
60	Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot study. <i>BMJ Open</i> , 2016, 6, e013483.	0.8	6
61	Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. <i>Lancet, The</i> , 2016, 388, 576-585.	6.3	296
62	Adipogenic Mesenchymal Stromal Cells from Bone Marrow and Their Hematopoietic Supportive Role: Towards Understanding the Permissive Marrow Microenvironment in Acute Myeloid Leukemia. <i>Stem Cell Reviews and Reports</i> , 2016, 12, 235-244.	5.6	34
63	Duration of first remission and hematopoietic cell transplantation-specific comorbidity index but not age predict survival of patients with AML transplanted in CR2: a retrospective multicenter study. <i>Bone Marrow Transplantation</i> , 2016, 51, 1019-1021.	1.3	5
64	Factors Influencing Long-Term Hematopoietic Function Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 2186-2186.	0.6	0
65	Quality of Life Scores Improve with Increasing Hemoglobin but Optimal Thresholds Vary According to Transfusion Dependence and Clinical Risk Scores: A Canadian Cross Sectional Study of 689 Patients with 2969 Measurements. <i>Blood</i> , 2016, 128, 3192-3192.	0.6	0
66	Low-Dose Anti-Thymocyte Globulin for Graft-Versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2016, 128, 5782-5782.	0.6	1
67	Impact of platelet transfusion on toxicity and mortality after hematopoietic progenitor cell transplantation. <i>Transfusion</i> , 2015, 55, 253-258.	0.8	14
68	Mesenchymal stromal cells from patients with acute myeloid leukemia have altered capacity to expand differentiated hematopoietic progenitors. <i>Leukemia Research</i> , 2015, 39, 486-493.	0.4	56
69	A single-institution analysis of the utility of pre-induction ejection fraction measurement in patients newly diagnosed with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 135-140.	0.6	6
70	Iron Chelation Is Associated with Improved Survival Adjusting for Disease and Patient Related Characteristics in Low/Int-1 Risk MDS at the Time of First Transfusion Dependence: A MDS-CAN Study. <i>Blood</i> , 2015, 126, 1701-1701.	0.6	4
71	Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study. <i>British Journal of Haematology</i> , 2014, 166, 660-666.	1.2	52
72	Systemic mastocytosis emerging after azacitidine treatment of refractory anaemia with excess blasts type 2. <i>British Journal of Haematology</i> , 2014, 167, 147-147.	1.2	3

#	ARTICLE	IF	CITATIONS
73	Autologous Stem Cell Transplantation for Stiff Person Syndrome. <i>JAMA Neurology</i> , 2014, 71, 1296.	4.5	29
74	Extended Dose-Total Body Irradiation (18Gy) Followed By an Allogeneic Cell Transplantation for the Treatment of Refractory Acute Myeloid Leukemia: Early Results. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S157-S158.	2.0	0
75	Favorable Outcomes from Allogeneic and Autologous Stem Cell Transplantation for Patients with Transformed Nonfollicular Indolent Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1813-1818.	2.0	16
76	Does Total Body Irradiation Conditioning Improve Outcomes of Myeloablative Human Leukocyte Antigenâ€Identical Sibling Transplantations for Chronic Lymphocytic Leukemia?. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 421-424.	2.0	13
77	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 202-208.	2.0	33
78	Outcomes of Human Leukocyte Antigenâ€Matched Sibling Donor Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia: Myeloablative Versus Reduced-Intensity Conditioning Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1390-1398.	2.0	18
79	Patient Related Factors Have an Independent Impact on Overall Survival in Myelodysplastic Syndrome Patients: A Report of the MDS-Can Registry. <i>Blood</i> , 2014, 124, 165-165.	0.6	1
80	Autologous Stem Cell Transplant for Myasthenia Gravis: A Single-Centre Experience. <i>Blood</i> , 2014, 124, 3996-3996.	0.6	16
81	P-116 Frailty is an independent prognostic marker for overall survival in MDS: Results of a Canadian MDS registry. <i>Leukemia Research</i> , 2013, 37, S76.	0.4	0
82	Autologous and Allogeneic Stem-Cell Transplantation for Transformed Follicular Lymphoma: A Report of the Canadian Blood and Marrow Transplant Group. <i>Journal of Clinical Oncology</i> , 2013, 31, 1164-1171.	0.8	92
83	Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. <i>Blood</i> , 2013, 122, 3863-3870.	0.6	153
84	Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?. <i>Blood</i> , 2013, 121, 2567-2573.	0.6	120
85	Acute Promyelocytic Leukemia In Canada: Poor Outcomes In Older Patients Remain. <i>Blood</i> , 2013, 122, 1714-1714.	0.6	0
86	Serial assessment of toxicity after hematopoietic SCT can discern kinetics of transplant-related organ injury and patterns of recovery. <i>Bone Marrow Transplantation</i> , 2012, 47, 1375-1376.	1.3	1
87	Vascular access devices in leukemia: a retrospective review amongst patients treated at The Ottawa Hospital with induction chemotherapy for acute leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1090-1095.	0.6	19
88	Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) in Chronic Lymphocytic Leukemia (CLL): Impact of Myeloablative (MA) Vs. Reduced-Intensity Conditioning (RIC) Regimens, and Impact of Total Body Irradiation (TBI)-Based MA Versus Chemotherapy (CT)-Based MA Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S290-S291.	2.0	0
89	Utility of Pre-Induction Cardiac Function Testing in Patients with Newly Diagnosed AML. <i>Blood</i> , 2012, 120, 2068-2068.	0.6	0
90	Comparison of Outcomes after Transplantation of G-CSFâ€Stimulated Bone Marrow Grafts versus Bone Marrow or Peripheral Blood Grafts from HLA-Matched Sibling Donors for Patients with Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1018-1024.	2.0	60

#	ARTICLE	IF	CITATIONS
91	HLA-matched sibling bone marrow transplantation for $\beta^2$ -thalassemia major. <i>Blood</i> , 2011, 117, 1745-1750.	0.6	114
92	Retrospective Review of Invasive Fungal Disease in a Cohort of Patients with Acute Leukemia. <i>Blood</i> , 2011, 118, 4265-4265.	0.6	7
93	Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. <i>Haematologica</i> , 2010, 95, 2119-2125.	1.7	137
94	The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. <i>Blood</i> , 2010, 116, 366-374.	0.6	178
95	Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. <i>Blood</i> , 2010, 116, 1839-1848.	0.6	168
96	Monoclonal B cells detected in autologous PBSC grafts from patients with classical Hodgkin lymphoma: impact on relapse and survival following transplantation. <i>Bone Marrow Transplantation</i> , 2010, 45, 856-861.	1.3	0
97	The Impact Of Prior Exposure To Rituximab On Autologous Stem Cell Transplantation In Patients With Follicular And Transformed Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, S198.	2.0	0
98	Contaminating tumour cells in autologous PBSC grafts do not influence survival or relapse following transplant for multiple myeloma or B-cell non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2009, 43, 223-228.	1.3	31
99	A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis. <i>Bone Marrow Transplantation</i> , 2009, 44, 317-320.	1.3	49
100	Bone Marrow Transplantation From HLA-Identical Sibling for Thalassemia.. <i>Blood</i> , 2009, 114, 3361-3361.	0.6	1
101	The Impact of Prior Exposure to Rituximab On Autologous Stem Cell Transplantation in Patients with Follicular and Transformed Follicular Lymphoma.. <i>Blood</i> , 2009, 114, 1230-1230.	0.6	0
102	Vascular Access Devices: A Retrospective Review Amongst Patients Treated at the Ottawa Hospital with Induction Chemotherapy for Acute Leukemia.. <i>Blood</i> , 2009, 114, 4521-4521.	0.6	0
103	Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. <i>Blood</i> , 2008, 112, 426-434.	0.6	80
104	Hematopoietic Recovery and Overall Survival after HLA-Matched Sibling Transplants for Older Patients with Severe Aplastic Anemia (SAA).. <i>Blood</i> , 2008, 112, 2169-2169.	0.6	1
105	A 15-Year Analysis of Early and Late Autologous Hematopoietic Stem Cell Transplant in Relapsed, Aggressive, Transformed, and Nontransformed Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 956-964.	2.0	56
106	Impact of Conditioning on the Outcome of Allografting in Myelofibrosis with Myeloid Metaplasia: Better Survival with Reduced Intensity Approach in Patients $\geq 50$ Years.. <i>Blood</i> , 2007, 110, 1095-1095.	0.6	0
107	A 15-year review of autologous stem cell transplant of advanced relapsed follicular lymphoma at the Ottawa hospital. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 115.	2.0	0
108	Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma. <i>Annals of Hematology</i> , 2006, 85, 723-729.	0.8	27

#	ARTICLE	IF	CITATIONS
109	Percent of Peripheral Blood Leukemic Blasts (PPBLB) at Diagnosis as a Predictor of Short- and Long-Term Survival in Acute Myeloid Leukemia (AML).. Blood, 2006, 108, 4449-4449.	0.6	0
110	A Randomized Trial Comparing the Effectiveness of Peripheral Blood Stem Cell Mobilization with Chemotherapy and Early vs Delayed Initiation of Granulocyte Colony-Stimulating Factor (G-CSF) in Patients with Lymphoma and Multiple Myeloma.. Blood, 2005, 106, 2929-2929.	0.6	0
111	The effect of plasmapheresis on the serum activity level of dalteparin: a case report. Blood Coagulation and Fibrinolysis, 2000, 11, 395-400.	0.5	15
112	Use of recombinant-hirudin in pulmonary thromboendarterectomy. Annals of Thoracic Surgery, 2000, 69, 1942-1943.	0.7	14
113	Anti-cruciform DNA affinity purification of active mammalian origins of replication. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1991, 1089, 299-308.	2.4	28